Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

ESH MM 2018 | Opinion: value of MRD as an endpoint in hem-onc clinical trials

Robert Hills • 5 Oct 2018

ESH MM 2018

General

Measurable residual disease (MRD) is a hot topic, with it’s full potential still to be fully realized. We spoke to Robert Hills from the University of Oxford, Oxford, UK, about his thoughts on the value of MRD as an endpoint in clinical trials in the hemato-oncology field. This interview took place at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.

UK NCRI AML17 trial update: everolimus addition for consolidation

UK NCRI AML17 trial update: everolimus addition for consolidation

Robert Hills • 5 Oct 2018

Judging the value of a clinical trial in hem-onc

Judging the value of a clinical trial in hem-onc

Robert Hills • 5 Oct 2018

Related Videos

Combining isatuximab, lenalidomide, oral cyclophosphamide, & dexamethasone for HR smoldering myeloma

Combining isatuximab, lenalidomide, oral cyclophosphamide, & dexamethasone for HR smoldering myeloma

Maher Salamoon • 9 Sep 2026

Treating peripheral T-cell lymphoma with chemotherapy, avelumab and brentuximab vedotin

Treating peripheral T-cell lymphoma with chemotherapy, avelumab and brentuximab vedotin

Maher Salamoon • 9 Sep 2026

Insights into the risk of pulmonary infections in patients with CLL treated with targeted agents

Insights into the risk of pulmonary infections in patients with CLL treated with targeted agents

Maher Salamoon • 8 Sep 2026

Key principles for implementing AI tools into clinical practice

Key principles for implementing AI tools into clinical practice

Adrián Mosquera Orgueira • 24 Sep 2026